Adam Zamecnik
Reporter
Adam has previously worked at GlobalData Media as a Healthcare Reporter, writing longer and shorter articles for the public website Pharmaceutical Technology and the Pharma Intelligence Centre. During his time there, Adam focused on topics such as cell and gene therapy, vaccine research, and new approaches to the treatment of haematological conditions. He has also covered the development of new biosimilars, the production of complex generics, and legal battles between Big Pharma. Prior to this, Adam wrote as a freelance reporter for the likes of Vice World News. Adam holds an MA in International Journalism from City, University of London.
Latest From Adam Zamecnik
Adalvo Hails First European Launch Of Prolonged-Release Pregabalin
After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.
Biosimilars Council Calls Out PBMs For Suppressing Humira Biosimilars Adoption
The US off-patent association published an analysis of IQVIA data, which highlights the role of rebate schemes that is slowing the adoption of Humira biosimilars that would save billions of dollars.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Mabwell Snaps Up China-First Approval For Xgeva Biosimilar
Following the drug’s earlier approval as a biosimilar to Prolia, China’s regulators greenlighted the use of Mabwell’s denosumab as a substitute for the second branded version, Xgeva, in its indications.
Mallinckrodt Reports 2023 Results After Second Restructuring
Emerging out of its second Chapter 11 bankruptcy filing in the past four years, the company reported a slump in net sales despite positive signals in specific portfolios.
China’s Regulators Accept Jiuyuan Gene’s Application For Ozempic Biosimilar
Jiuyuan Gene scored a country-wide first as China’s regulator accepted its marketing application for a semaglutide biosimilar in type 2 diabetes that will be marketed as Jiyoutai.